‫ تحفة شركة Wemade لألعاب ال MMORPG لعبة MIR4 تكشف عن محتوى PVP جديد – Bicheon Heist

تم الكشف عن محتوى PVP جديد للعشيرة ل !MIR4

سيول، كوريا الجنوبية، 28 يونيو 2022  — /PRNewswire/ سيتم الكشف عن محتوى PVP جديد من لعبة MIR4 ، وهو Bicheon Heist ، في 28 يونيو 2022.

“دافع عن Darksteel أو تعرض للسرقة!”

إضافة إثارة جديدة إلى قارة MIR Bicheon Heist كل يوم جمعة من الساعة 10 مساء حتى الساعة 11 مساء بدءا من 1 يوليو. تم فتح قبو Darksteel تحت الأرض في قلعة Bicheon ، ويجب على العشيرة التي تحكم قلعة Bicheon ، جنبًا إلى جنب مع حلفائها، الدفاع ضد مخططات Heisters الذين يسعون إلى نهب Darksteel من القبو. أفضل 20 عشيرة في الخادم غير متحالفة مع المدافعين قادرة على المشاركة كـ Heisters .

إذا دمر ال Heisters البوابة الحديدية التي تسد مدخل قبو Darksteel وهزم الوصي الرئيسي المهدد “ Cheol Mujin ” الذي يحرس Darksteel ، فستكون العديد من صناديق Darksteel ملكًا لهم. يمكن أيضًا الحصول على مكافآت إضافية مثل قطع الكنز الأسطوري والأحجار الصوفية والأحجار المظلمة التي تحتوي على المواد اللازمة لصياغة كنوز الروح الأسطورية.

كما تمت إضافة بعثات حصرية لمحتوى إكسبيديشن. يمكن للاعبين تجربة مهام أكثر تنوعًا عبر الخوادم وسيتلقون غنائم وفيرة للمساعدة في تقدم شخصياتهم أثناء إكمالهم لهذه المهام.

سيتم أيضًا تقديم بطل الرياح الأسطورية الجديد وهو Dark Crown ولي عهد Wooska خلال التحديث. بطل الرياح الأسطورية هذ صعب للغاية ومتخصص للغاية في الدفاع البدني. للاحتفال بإصدار Dark Crown ولي عهد Wooska ، ستصبح علامة تبويب استدعاء خاص متاحة حتى تحديث 26 يوليو. عندما يتم استدعاء الروح الأسطورية من خلال الاستدعاء الخاص خلال هذه الفترة، سيكون لدى اللاعبين فرصة بنسبة 100% للحصول على الروح الجديدة والبطل Dark Crown ولي عهد Wooska .

من معركتي إلى حربنا! يمكن العثور على مزيد من المعلومات حول MIR4 على الموقع الرسمي.

الصورة –  https://mma.prnewswire.com/media/1848099/MIR4_Update_image.jpg

الشعار –  https://mma.prnewswire.com/media/1848100/MIR4_Logo.jpg

Pfizer Signs New $3.2B Covid Vaccine Deal With US Government

Pfizer Inc. and partner BioNTech said on Wednesday they signed a $3.2 billion deal with the U.S. government for 105 million doses of their COVID-19 vaccine, which could be delivered as soon as later this summer.

The deal includes supplies of a retooled omicron-adapted vaccine, pending regulatory clearance, according to Pfizer.

Drugmakers have been developing vaccines to target the omicron variant that became dominant last winter.

The average price per dose in the new deal is over $30, a more than 50% increase from the $19.50 per dose the U.S. government paid in its initial contract with Pfizer.

Some of the vaccine earmarked for adults included in the contract will be in single-dose vials, which are more expensive to manufacture but reduce waste of unused shots from open vials.

“We look forward to taking delivery of these new variant-specific vaccines and working with state and local health departments, pharmacies, healthcare providers, federally qualified health centers, and other partners to make them available in communities around the country this fall,” U.S. Department of Health and Human Services official Dawn O’Connell said in a statement.

Advisers to the U.S. Food and Drug Administration on Tuesday recommended a change in the design of COVID-19 booster shots for this fall in order to combat more recently circulating variants of the coronavirus.

The U.S. government also has the option to purchase up to 195 million additional doses, bringing the total number of potential doses to 300 million, the companies said.

The new contract should boost 2022 vaccine sales for Pfizer and BioNTech, which share profits from the shots. Pfizer has forecast COVID-19 vaccine sales of $32 billion this year. Analysts, on average, have forecast 2022 sales of around $33.6 billion for the shots.

The U.S. government has distributed close to 450 million doses of the Pfizer-BioNTech vaccine in the United States since it was first authorized in December 2020, according to data from the U.S. Centers for Disease Control and Prevention. More than 350 million of those doses have been administered.

Because the Biden administration was unable to line up more COVID-19 funding from Congress earlier this month, it was forced to reallocate $10 billion of existing funding to pay for additional vaccines and treatments.

According to the Department of Health and Human Services, the money to pay for doses in this new contract comes from that funding.

Source: Voice of America

Scientists’ Model Uses Google Search Data to Forecast COVID Hospitalizations

Future waves of COVID-19 might be predicted using internet search data, according to a study published in the journal Scientific Reports.

In the study, researchers watched the number of COVID-related Google searches made across the country and used that information, together with conventional COVID-19 metrics such as confirmed cases, to predict hospital admission rates weeks in advance.

Using the search data provided by Google Trends, scientists were able to build a computational model to forecast COVID-19 hospitalizations. Google Trends is an online portal that provides data on Google search volumes in real time.

“If you have a bunch of people searching for ‘COVID testing sites near me’ … you’re going to still feel the effects of that downstream at the hospital level in terms of admissions,” said data scientist Philip Turk of the University of Mississippi Medical Center, who was not involved in the study. “That gives health care administrators and leaders advance warning to prepare for surges — to stock up on personal protective equipment and staffing and to anticipate a surge coming at them.”

For predictions one or two weeks in advance, the new computer model stacks up well against existing ones. It beats the U.S. Centers for Disease Control and Prevention’s “national ensemble” forecast, which combines models made by many research teams — though there are some single models that outperform it.

Different perspective

According to study co-author Shihao Yang, a data scientist at the Georgia Institute of Technology, the new model’s value is its unique perspective — a data source that is independent of conventional metrics. Yang is working to add the new model to the CDC’s COVID-19 forecasting hub.

Watching trends in how often people Google certain terms, like “cough” or “COVID-19 vaccine,” could help fill in the gaps in places with sparse testing or weak health care systems.

Yang also thinks that his model will be especially useful when new variants pop up. It did a good job of predicting spikes in hospitalizations thought to be associated with new variants such as omicron, without the time delays typical of many other models.

“It’s like an earthquake,” Yang said. “Google search will tell me a few hours ahead that a tsunami is hitting. … A few hours is enough for me to get prepared, allocate resources and inform my staff. I think that’s the information that we are providing here. It’s that window from the earthquake to when the tsunami hit the shore where my model really shines.”

The model considers Google search volumes for 256 COVID-19-specific terms, such as “loss of taste,” “COVID-19 vaccine” and “cough,” together with core statistics like case counts and vaccination rates. It also has temporal and spatial components — terms representing the delay between today’s data and the future hospitalizations it predicts, and how closely connected different states are.

Every week, the model retrains itself using the past 56 days’ worth of data. This keeps the model from being weighed down by older data that don’t reflect how the virus acts now.

Turk previously developed a different model to predict COVID-19 hospitalizations on a local level for the Charlotte, North Carolina, metropolitan area. The new model developed by Yang and his colleagues uses a different method and is the first to make state- and national-level predictions using search data.

Turk was surprised by “just how harmonious” the result was with his earlier work.

“I mean, they’re basically looking at two different models, two different paths,” he said. “It’s a great example of science coming together.”

Using Google search data to make public health forecasts has downsides. For one, Google could stop allowing researchers to use the data at any time, something Yang admits is concerning to his colleagues.

‘Noise’ in searches

Additionally, search data are messy, with lots of random behavior that researchers call “noise,” and the quality varies regionally, so the information needs to be smoothed out during analysis using statistical methods.

Local linguistic quirks can introduce problems because people from different regions sometimes use different words to describe the same thing, as can media coverage when it either raises or calms pandemic fears, Yang said. Privacy protections also introduce complications — user data are aggregated and injected with extra noise before publishing, a protection that makes it impossible to fish out individual users’ information from the public dataset.

Running the model with search data alone didn’t work as well as the model with search data and conventional metrics. Taking out search data and using only conventional COVID-19 metrics to make predictions also hurt the new model’s performance. This indicates that, for this model, the magic is in the mix — both conventional COVID-19 metrics and Google Trends data contain information that is useful for predicting hospitalizations.

“The fact that the data is valuable, and [the] data [is] difficult to process are two independent questions. There [is] information in there,” Yang said. “I can talk to my mom about this. It’s very simple, just intuitive. … If we are able to capture that intuition, I think that’s what makes things work.”

Source: Voice of America

Malawi receives US$14.2 million drought recovery insurance payout

The African Risk Capacity Group and the African Development Bank make a $14.2 million drought recovery insurance payout to the Government of Malawi

JOHANNESBURG 29 June 2022 — In a ceremony presided over by His Excellency, the President of the Republic of Malawi, Dr Lazarus McCarthy Chakwera, the Chairperson and Deputy Chairperson of the African Risk Capacity Group, in the presence of Representatives of Partners organisations (Ambassador of Germany to Malawi), and of the UN system (WFP and UNDP country directors), delivered a symbolic US$14.2 million insurance payout cheque to the Malawi Government.

*”I assured Malawians that we have enough food for everyone and even those few whose crops had not done well would be provided for. My confidence came from the fact that we had taken this insurance policy to support Malawians in time of need. And I want to thank the ARC Group for honouring the agreed payout,” *said His Excellency, Dr Lazarus McCarthy Chakwera, President of the Republic of Malawi.

The Government of Malawi had a drought insurance policy, supported by the African

Development Bank through its Africa Disaster Risk Financing (ADRiFi) Programme Multi-Donor Trust Fund. Many regions of Malawi, particularly the Central and Southern regions, are experiencing severe food insecurity caused by drought-related events like erratic rainfall and crop failure.

The Governments of the United Kingdom, through the Foreign, Commonwealth and Development Office, and Switzerland, through the Swiss Agency for Development and Corporation contributed to the ADRiFi trust fund. The Government of Germany, through KFW Development Bank/Federal Ministry for Economic Cooperation and Development, as well as the International Fund for Agricultural Development subsidized Malawi’s insurance policy premiums.

During the 2020/21 season, the country experienced an unprecedented dry start to the production season, leading to higher rates of sowing failure in significant parts of the Southern and the Central Regions as modelled by Africa RiskView, the African Risk Capacity Group’s (ARC) risk modelling and early warning tool. This, combined with mid-season erratic rainfall conditions in most parts of the country resulted in a modelled number of people affected estimated at about 6.4 million, the second-highest number of affected people, since 2001.

*”ARC’s drought insurance mechanism is an innovative pan-African tool that provides our member states with the funds needed to better plan, prepare and respond to climate-related disasters,” *said ARC Group Board Chairperson, Dr. Anthony Mothae Maruping. *”The payout to the Government of Malawi will not only release pressure on public finances but it will also bring nutritional and financial support to those that have been affected by the droughts caused by an increasingly variable and changing climate,” *he added.

*”Malawi is a signatory of the ARC Treaty and a key partner in the region. We have no doubt that the funds disbursed will support the country in scaling up its response to the drought-induced challenges,” *said United Nations Assistant Secretary-General and ARC Group Director General, Ibrahima Cheikh Diong.

*”ARC’s drought insurance product ensures the swift release of funds when they are needed most, allowing them to be channelled effectively to respond to a crisis. The most vulnerable in the country, who are facing severe hunger, will now have access to food relief,” *declared Lesley Ndlovu, CEO of ARC Limited, the insurance affiliate of the ARC Group.

Source: Government of Malawi

Citeline and Norstella Unite to Offer Life Sciences Clients a Full Suite of Commercial and Clinical Solutions

The new organization will help life sciences companies improve strategic decision-making and accelerate the mission of smoothing access to therapy from pipeline to patient

Yardley, PA, June 28, 2022 (GLOBE NEWSWIRE) — Norstella, an organization that helps life sciences companies navigate the complexities of the drug life cycle, and Citeline (formerly Pharma Intelligence)—a leading provider of specialist intelligence, data and software for clinical trials, drug development and regulatory compliance—have announced an agreement to merge the companies.

By uniting Norstella, which is comprised of four prominent pharmaceutical solutions providers—EvaluateMMITPanalgo and The Dedham Group—with Citeline, the combined company will be well positioned to help life sciences companies reach patients faster by providing clients with the intelligence and answers they need from early clinical development through to commercialization. This move reflects the shared goal of becoming an end-to-end solution provider, helping patients access life-saving therapies.

As life sciences companies drive innovation toward more specialized therapeutics across all disease areas including oncology and rare disease, and patient populations become more targeted, they need to make critical decisions about how to bring the right drugs to market, how to construct clinical trials leveraging the latest innovations in real-world data and data science—and with end points that consider future payer reimbursement decisions—and, ultimately, how to reach patients in need.

“Accelerating innovation and ensuring that every patient gets the therapy that they need is our North Star,” said Norstella CEO Mike Gallup. “By bringing clinical and commercial intelligence together—along with real-world data—the combined company will be well positioned to deliver on its mission.”

Together, Norstella and Citeline will play a critical role in helping pharmaceutical manufacturers plan for and overcome barriers to access, not just during clinical trials but at every stage in the drug development life cycle. Citeline’s solutions, including its portfolio of clinical trial products, provide insights that improve the speed and efficiency of clinical trials and reduce risk. Now, the Citeline solutions—along with MMIT’s PAR data and other complementary Norstella data assets—can be powered by Panalgo’s Instant Health Data Analytics platform to provide transformative answers that will improve workflow and decision-making and, ultimately, help products get to market and to patients quicker than ever before.

“At Citeline, our mission is to accelerate the connection of treatments to patients and patients to treatments. Ultimately, this marriage of commercial and clinical capabilities will advance the mission and enable the pharmaceutical C-suite to manage portfolio strategy like never before,” said Ramsey Hashem, CEO, and Jay Nadler, Executive Chair, of Citeline. “This includes deciding which drug to bring to market, what new indications to pursue for a drug and how to target patients for clinical trials more quickly and with reduced cost. And now, this includes understanding how to design clinical trials that yield the types of data that payers need to make appropriate reimbursement and formulary decisions.”

“It’s about making a difference in the lives of patients,” said Gallup. “This move will help us make our vision of a more innovative, accessible healthcare marketplace a reality.”

The merger is expected to close in the second half of 2022 subject to customary closing conditions and regulatory approvals.

About Norstella
At Norstella, our mission is simple: to help patients gain access to life-saving therapies. Norstella consists of several prominent organizations—Evaluate, MMIT, Panalgo and The Dedham Group—that have united to offer a full range of pharmaceutical consultancy services and solutions. As one organization, Norstella provides life sciences clients with the right tools and expertise to navigate complexities at each step of the drug development life cycle, from pipeline to patient. For more information, visit Norstella and follow on LinkedIn.

About Citeline
Citeline (formerly Pharma Intelligence) powers a full suite of complementary business intelligence offerings to meet the evolving needs of health science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory related-decisions and create real-world opportunities for growth.

Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. For more information on one of the world’s most trusted health science partners, visit Citeline.

Melody Udell
Norstella
312-618-5968
melody.udell@norstella.com

Blair Dawson
Citeline
919-413-4616
blair.dawson@informa.com

Seegene develops PCR test to detect monkeypox virus

  • Assay targets monkeypox virus and can deliver results in 90 minutes
  • Company swiftly rolls out product using its automated assay development system
  • “Seegene will strive to make accurate tests for emerging viruses to help prevent future pandemics”

SEOUL, South Korea, June 28, 2022 /PRNewswire/ — Seegene Inc. (KQ965390), South Korea’s leading molecular diagnostics (MDx) company has developed a PCR test to detect the monkeypox virus. The Novaplex™ MPXV Assay, which specifically targets the monkeypox virus, was swiftly developed using the company’s AI-based automated test development system, known as SGDDS (Seegene Digitalized Development System), and technologies refined over 20 years of MDx expertise.

Logo

The World Health Organization says the monkeypox virus is an “evolving health threat that requires collective attention and coordinated action,” calling on member states to step up surveillance, contact tracing and testing. The monkeypox virus has been detected in over 50 nations, with South Korea confirming its first case last week. The strain currently circulating in the Northern Hemisphere has an estimated fatality rate of between 3-6 percent and is considered especially dangerous for children and those with weak immune systems.

As with many infectious diseases, accurate diagnosis is crucial as treatments are more effective in the early stages of infection. This makes timely PCR testing vital, especially for individuals with a suspected case, as the incubation period for the monkeypox infection ranges between five to 21 days.

The Novaplex™ MPXV Assay can identify positive cases of the monkeypox virus in 90 minutes. The company swiftly developed the product to help curb the worldwide spread. Seegene plans to provide the assays to countries that have detected the virus.

“The monkeypox virus outbreak shows that endemic viruses can rapidly spread to the rest of the world and it’s a warning that new pandemics can emerge and threaten our lives at any time,” said Dr. Jong-Yoon Chun, CEO of Seegene. “We will continue our efforts to develop products that can accurately diagnose any virus to help prevent new infectious diseases from taking hold and becoming a pandemic.”

Logo – https://mma.prnewswire.com/media/1357790/Seegene_logo_Logo.jpg